• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Phathom Pharmaceuticals, Inc. - Common Stock (NQ: PHAT )

    7.500 -0.110 (-1.45%)
    Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Phathom Pharmaceuticals, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 Next >
    Top Biotech Short Squeeze Stocks
    Investing in biotechnology stocks offers a unique opportunity for individuals looking to gain exposure to one of the most dynamic and innovative sectors of the market. 
    Via Talk Markets
    Topics Stocks / Equities
    Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Preview: Phathom Pharmaceuticals's Earnings
    Via Benzinga
    Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    These Are The Top 3 Most-Shorted Stocks In August 2024; Here’s Why
    Short-squeeze opportunities are tough to find. Combine market timing with fundamentals for these stocks. 
    Via Talk Markets
    Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    PHAT Stock Earnings: Phathom Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
    PHAT stock results show that Phathom Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
    Via InvestorPlace
    Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Added to CVS Caremark Formularies for Commercially Insured Patients
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Phathom Pharmaceuticals to Report Second Quarter 2024 Financial Results and Provide Business Update on Thursday, August 8, 2024
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Ready for Quick Gains? 7 Top Short-Squeeze Stocks to Watch Now
    Each of the following seven heavily-shorted stocks may have what it takes to become one of the next big short squeeze stocks. 
    Via InvestorPlace
    Ride the Gamma Wave: 3 Stocks on the Verge of a Short Squeeze
    Though short squeezes are never guaranteed, these three potential short squeeze stocks could provide generous returns if bought right. 
    Via InvestorPlace
    Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2024 Annual Meeting
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    The 3 Best Healthcare Stocks to Buy in May 2024
    Healthcare firms can make large amounts of money, particularly in the U.S. Here are the three best healthcare stocks to buy now. 
    Via InvestorPlace
    PHAT Stock Earnings: Phathom Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024
    PHAT stock results show that Phathom Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
    Via InvestorPlace
    Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Phathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”
    National TV and digital media campaign aims to motivate millions of people suffering from Erosive GERD to learn more about VOQUEZNA® (vonoprazan), the first and only FDA-approved potassium-competitive... 
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    PHAT Stock Earnings: Phathom Pharmaceuticals Misses EPS, Beats Revenue for Q4 2023
    PHAT stock results show that Phathom Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023. 
    Via InvestorPlace
    Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Earnings Scheduled For March 7, 2024
    Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million. 
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.